Virus inactivation in the 1990s - And into the 21st century: Part 6, inactivation methods grouped by virus

BioPharm International

Volumn 16, Issue 4, 2003, Pages 42-52+68

  Sofer, Gail ^a   Lister, Dorothy C ^a   Boose, Jeri Ann ^a  

^a BioReliance   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; VIRUS RNA;

DRUG MANUFACTURE; FREEZE DRYING; HEPATITIS A VIRUS; MURINE LEUKEMIA VIRUS; NONHUMAN; PARVOVIRUS; PH; PSEUDORABIES HERPETOVIRUS; REOVIRUS; REVIEW; TEMPERATURE DEPENDENCE; VIRUS ENVELOPE; VIRUS INACTIVATION;

EID: 0037391331     PISSN: 1542166X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Sofer, G., "Virus Inactivation in the 1990s - and into the 21st Century, Part 1: Skin, Bone, and Cells," BioPharm 15(7), 18-24 (July 2002).
2. Sofer, G., "Virus Inactivation in the 1990s - and into the 21st Century, Part 2: Red Blood Cells and Platelets," BioPharm 15(8), 42-49 (August 2002).
3. Sofer, G., "Virus Inactivation in the 1990s - and into the 21st Century, Part 3a: Plasma and Plasma Products (Heat and Solvent/Detergent Treatments)," BioPharm 15(9), 28-42 (September 2002).
4. Sofer, G., "Virus Inactivation in the 1990s - and into the 21st Century, Part 3b: Plasma and Plasma Products (Treatments Other than Heat or Solvent/Detergent)," BioPharm 15(10), 42-49, 51 (October 2002).
5. Sofer, G., "Virus Inactivation in the 1990s - and into the 21st Century, Part 4: Culture Media, Biotechnology Products, and Vaccines," BioPharm Int. 16(1), 50-57 (January 2003).
6. Sofer, G., "Virus Inactivation in the 1990s - and into the 21st Century, Part 5: Disinfection," BioPharm Int. 16(2), 44-48, 71 (February 2003).
7. Blumel, J. et al., "Inactivation of Parvovirus B19 During Pasteurization of Human Serum Albumin," Transfusion 42, 1011-1018 (2002).
8. Chang, C.E. et al., "Human Intravenous Immunoglobulin Preparation and Virus Inactivation by Pasteurization and Solvent Detergent Treatment," Prep. Biochem. Biotechnol. 30(3), 177-197 (2000).
9. Coan, M.H. et al., "Characterisation and Virus Safety of Alpha 1-Proteinase Inhibitor," Eur. Respir. J. Suppl., 35s-38s (9 March 1990).
10. 50 Assay," J. Med. Virol. 49(1), 1-6 (1996).
11. Savage, M. et al., "Determination of Adequate Moisture Content for Efficient Dry-Heat Viral Inactivation in Lyophilized Factor VIII by Loss on Drying and by Near Infrared Spectroscopy," Biologicals 2, 119-124 (1998).
12. Roberts, P.L., "Comparison of the Inactivation of Canine and Bovine Parvovirus by Freeze-Drying and Dry-Heat Treatment in Two High Purity Factor VIII Concentrates," Biologicals 3, 185-188 (2000).
13. Dichtelmuller, H. et al., "Improvement of Virus Safety of a S/D-Treated Factor VIII Concentrate by Additional Dry Heat Treatment at 100°C," Biologicals 2, 125-130 (1996).
14. Borovec, S. et al., " Inactivation Kinetics of Model and Relevant Blood-borne Viruses by Treatment with Sodium Hydroxide and Heat," Biologicals 3, 237-244 (1998).
15. Van Engelenburg, F. et al., "Evaluation and Development of Sanitization Conditions for Chromatography and Filtration Steps," paper presented at the PDA/FDA Viral Clearance Forum in Bethesda, MD, 1-3 October 2001.
16. Willkommen, H. et al., "Serum and Serum Substitutes: Virus Safety by Inactivation or Removal," Dev. Biol. Stand. 99, 131-138 (1999).
17. Marx, G. et al., "Protecting Fibrinogen with Rutin During UVC Irradiation for Viral Inactivation," Photochem. Photobiol. 63(4), 541-546 (1996).
18. Chin et, S. et al., "Virucidal Short Wavelength Ultraviolet Light Treatment of Plasma and Factor VIII Concentrate: Protection of Proteins by Antioxidants," Blood 86(11), 4331-4336 (1995).
19. Kurth, J. et al., "Efficient Inactivation of Viruses and Mycoplasma in Animal Sera Using UVC Irradiation," Dev. Biol. Stand. 99, 111-118 (1999).
20. Miekka, S.I. et al., "New Methods for Inactivation of Lipid-Enveloped and Nonenveloped Viruses," Haemophilia 4(4), 402-408 (1998).
21. Council of Europe, Pestivirus Contamination of Bovine Sera and Other Bovine Virus Contamination Proceedings (Proceedings of the International Symposium Organized by the European Directorate for the Quality of Medicines, Paris, 29-30 March 2001).
22. Pruss, A. et al, "Effect of Gamma Irradiation on Human Cortical Bone Transplants Contaminated with Enveloped and Nonenveloped Viruses," Biologicals 30, 125-133 (2002).
23. Preuss, T. et al., "Comparison of Two Different Methods for Inactivation of Viruses in Serum," Clin. Diagn. Lab. Immunol. 4(5), 504-508 (1997).
24. Bahnemann, H.G., "Inactivation of Viral Antigens for Vaccine Preparation with Particular Reference to the Application of Binary Ethylenimine," Vaccine 8, 299-303 (1990).
25. Edson, C.M. et al., "Viral Inactivation in Red Blood Cell Concentrates by Inactine," Transfusion 39(suppl.), 108s (1999).
26. Animal Viruses & Antisera Chlamydiae & Rickettsiae, 7th ed., G. McDaniel, C. Buck, and H. Khouri, Eds. (American Type Culture Collection, Rockville, MD, 1996).
27. Kurth, J. et al., "Efficient Inactivation of Viruses and Mycoplasma in Animal Sera Using UVC Irradiation," Dev. Biol. Stand. 99, 111-118 (1999).
28. Mohr, H., "Inactivation of Viruses in Human Plasma," Methods Enzymol. 319, 207-216 (2000).
29. Neighbor, N.K. et al., "The Effect of Microaerosolized Hydrogen Peroxide on Bacterial and Viral Poultry Pathogens," Poult. Sci. 73(10), 1511-1516 (1994).
30. Skladanek, M. "Viral Inactivation Utilizing Depth Filter Media Containing a PVPP-Iodine Complex," paper presented at the PDA/FDA Viral Clearance Forum, Bethesda, MD, 1-3 October 101. Bethesda, MD
31. Nowak, T. et al., "Inactivation of HIV, HBV, HCV Related Viruses and Other Viruses in Human Plasma Derivatives by Pasteurisation," Dev. Biol. Stand. 81, 169-176 (1993).
32. Adcock, W.L. et al., "Chromatographic Removal and Heat Inactivation of Hepatitis A Virus During Manufacture of Human Albumin," Biotechnol. Appl. Biochem. 28, 85-94 (1998).
33. Wilfenhaus, J. and Nowak, T., "Inactivation of Hepatitis A Virus by Pasteurization and Elimination of Picornaviruses During Manufacture of Factor VIII Concentrate," Vox Sang. 67(suppl. 1), 62-66 (1994).
34. Biesert, L. et al., "Viral safety of a New Highly Purified Factor VIII (OCTATE)," J. Med. Virol. 48(4), 360-366 (1996).
35. Biesert, L. et al., "Virus Validation Experiments on the Production Process of OCTAVI SDPlus," Blood Coagul. Fibrinolysis 6(suppl. 2), s48-s54 (1995).
36. Hart, H.F. et al., "Effect of Terminal (Dry) Heat Treatment on Nonenveloped Viruses in Coagulation Factor Concentrates," Vox Sang. 67(4), 345-350 (1994).
37. Santagostino, E. et al., "Transmission of Parvovirus B19 by Coagulation Factor Concentrates Exposed to 100 Degrees C Deat After Lyophilization," Transfusion 37(5), 517-522 (1997).
38. Arrighi, S. et al., "In Vitro and In Animal Model Studies on a Double Virus-inactivated Factor VIII Concentrate," Thromb. Haemost. 74(3), 868-873 (1995).
39. Barrett, P.N. et al., "Inactivation of Hepatitis A Virus in Plasma Products by Vapor Heating," Transfusion 37(2), 215-220 (1997).
40. Rosenthal, S. et al., "Pasteurization of Cohn Fraction V Products: Effect of pH on Viral Inactivation Efficacy," poster presentation at the PDA/FDA Viral Clearance Forum, Bethesda, MD, 1-3 October 2001.
41. Scarborough, N.L. et al., "Allograft Safety: Viral Inactivation with Bone Demineralization," Contemp. Orthop. 31(4), 257-261 (1995).
42. Andre, F.E. et al., "Inactivated Candidate Vaccines for Hepatitis A," Progr. Med. Virol. 37, 72-95 (1990).
43. Pellegrini, V. et al., "Preparation and Immunogenicity of an Inactivated Hepatitis A Vaccine," Vaccine 11(3), 383-387 (1993).
44. Roberts, C. and Antonoplos, P., "Inactivation of Human Immunodeficiency Virus Type-1, Hepatitis A Virus, Respiratory Syncytial Virus, Vaccinia Virus, Herpes Simplex Virus Type-1, and Poliovirus Type-2 by Hydrogen Peroxide Gas Plasma Sterilization," Am. J. Infect. Control 26(2), 94-101 (1998).
45. Abujoub, A. et al., "Factors Affecting the Kinetics of Xenotropic Murine Leukemia Virus Inactivation by Low pH: The Role of pH Range, Temperature, Protein Concentration, and Product," paper presented at the PDA/FDA Viral Clearance Forum, Bethesda, MD, 1-3 October 2001.
46. Hilfenhaus, J., "Inactivation of Retroviruses in Biologicals Manufactured for Human Use," Dev. Biol. Stand. 75, 159-169 (1991).
47. Horowitz, B. et al., "Viral Safety of Solvent-detergent Treated Blood Products," Dev. Biol. Stand. 81, 147-161 (1993).
48. Charlebois, T.S. et al., "Viral Safety of B-Domain Deleted Recombinant Factor VIII," Semin. Hematol. 38(2) 32-39 (2001).
49. Dorner, F. and Barrett, N., "Viral Inactivation and Partitioning in the Manufacture of Coagulation Factor Concentrates," Hamostaseologie 16, 282-285 (1996).
50. Reindel, K., "Generic Approach to Viral Clearance Studies," paper presented at the PDA/FDA Viral Clearance Forum, Bethesda, MD, 1-3 October 2001.
51. Omar, A. et al., "Virus Inactivation by Pepsin Treatment at pH 4 of IgG Solutions: Factors Affecting the Rate of Virus Inactivation," Transfusion 36(10), 866-872(1996).
52. Dodd, R.Y. et al., "Inactivation of Viruses in Platelet Suspensions that Retain Their In Vitro Characteristics: Comparison of Psoralen-Ultraviolet A and Merocyanine 540-Visible Light Methods," Transfusion 31(6),483-490 (1991).
53. Wagner, S.J. et al., "Preservation of Red Cell Properties After Virucidal Phototreatment with Dimethylmethylene Blue," Transfusion 38(8), 729-737 (1998).
54. Dichtelmuller, H. et al., "Validation of Virus Inactivation and Removal for the Manufacturing Procedure of Two Immunoglobulins and a 5% Serum Protein Solution Treated with Beta-Propiolactone," Biologicals 21(3), 259-268 (1993).
55. Highsmith, F. et al., "Iodine-Mediated Inactivation of Lipid- and Nonlipid-Enveloped Viruses in Human Antithrombin III Concentrate," Blood 86(2), 791-796 (1995).
56. Fages, J. et al., "Viral Inactivation of Human Bone Tissue Using Supercritical Fluid Extraction," ASAIO J. 44(4), 289-293 (1998).
57. Moroff, G. et al., "Factors Influencing Virus Inactivation and Retention of Platelet Properties Following Treatment with Aminomethyltrimethylpsoralen and UVA," Blood Cells 18, 43-56 (1992).
58. Pamphilon, D., "Viral Inactivation of Fresh Frozen Plasma," Br. J. Haematol. 109(4), 680-693 (2000).
59. Biesert, L. and Suhartono, H., "Solvent/Detergent Treatment of Human Plasma - A Very Robust Method for Virus Inactivation: Validated Virus Safety of OCTAPLAS," Vox Sang. 74(suppl. 1), 207-212 (1998).
60. Alonso, W.R. et al., "Viral Inactivation of Intramuscular Immune Serum Globulins," Biologicals 28(1), 5-15 (2000).
61. Stucki, M. et al., "Characterisation of a Chromatographically Produced Anti-D Immunoglobulin Product," J. Chromatogr. B Biomed. Sci. Appl. 700(1-2), 241-248 (1997).
62. Korneyeva, M. et al., "Enveloped Virus Inactivation by Caprylate: A Robust Alternative to Solvent-Detergent Treatment in Plasma-Derived Intermediates," Biologicals 30, 153-162 (2002).
63. Dichtelmuller, H. et al., "Inactivation of Lipid Enveloped Viruses by Octanoic Acid Treatment of Immunoglobulin Solution," Biologicals 30, 135-142 (2002).
64. Corash, L., "Inactivation of Infectious Pathogens in Labile Blood Components," Transfus. Clin. Biol. 8, 138-45 (2001).
65. Morgenthaler, J.-J., "Securing Viral Safety for Plasma Derivatives," Transfus. Med. Rev. 15(3), 224-233 (2001).
66. Council of Europe, Expert Committee in Blood Transfusion Study Group on Pathogen Inactivation of Labile Blood Components, "Pathogen Inactivation of Labile Blood Components," Transfus. Med. 11, 149-175 (2001).